The potential of beta-glucan intake in the prevention of viral diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020660

Enrollment

Registered

2016-01-25

Start date

2016-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza and norovirus-related gastroenteritis

Interventions

The participants ingest 50mg of beta-glucan twice a day for 6 months via either a naso-gastric tube, gastric fistula or intestinal fistula. No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving nutrition via naso-gastric tube, gastric fistula or intestinal fistula at a long-term care hospital

Exclusion criteria

Exclusion criteria: Patients whose condition is unstable

Design outcomes

Primary

Measure	Time frame
Whether or not the patient develops influenza and/or norovirus-related gastroenteritis within 6 months after beginning the trial	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026